53,994 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Bought by Dark Forest Capital Management LP

Dark Forest Capital Management LP acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 53,994 shares of the company's stock, valued at approximately $654,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ELAN. Wilmington Savings Fund Society FSB purchased a new position in shares of Elanco Animal Health in the third quarter worth about $35,000. Jones Financial Companies Lllp raised its holdings in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after acquiring an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. lifted its stake in Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock worth $60,000 after purchasing an additional 3,411 shares in the last quarter. MRP Capital Investments LLC acquired a new position in shares of Elanco Animal Health during the 4th quarter worth approximately $61,000. Finally, Blue Trust Inc. grew its position in shares of Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after purchasing an additional 1,894 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the company's stock in a transaction on Tuesday, March 11th. The stock was acquired at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares in the company, valued at approximately $1,136,881.80. The trade was a 9.86 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.89% of the company's stock.

Elanco Animal Health Trading Down 0.5 %

ELAN stock traded down $0.05 during mid-day trading on Thursday, hitting $9.44. 696,775 shares of the company were exchanged, compared to its average volume of 4,927,192. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $18.80. The firm has a market capitalization of $4.68 billion, a P/E ratio of 23.61, a PEG ratio of 2.50 and a beta of 1.44. The business has a fifty day simple moving average of $9.94 and a 200-day simple moving average of $11.56. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same period in the previous year, the business posted $0.08 EPS. The business's revenue for the quarter was down 1.4% on a year-over-year basis. On average, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

ELAN has been the topic of a number of recent research reports. UBS Group lowered their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Barclays lowered their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Piper Sandler dropped their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Stifel Nicolaus reduced their target price on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Finally, Morgan Stanley dropped their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $14.67.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.